2012 medicine- a competitive advantage is king.docVIP

 PAGE \* MERGEFORMAT 5 2012 medicine: a competitive advantage is king Look at the basis of China’s pharmaceutical industry face the situation in 2011: January to August 2011, cumulative production of chemical raw materials of the country over the previous year increased by 24.35% over the previous year’s growth rate rose 4.12 percentage points month in August than in the national production of chemical raw materials to reduce production in July of 40,900 tons, the chain growth -16.25% in July. medicine’s cumulative production up 32.48% over the previous year, an increase year on year increase of 9.59 percentage points, the development of better, but the month of August, down by proprietary production 1.96 million tons, production chain growth -9.39% in July. I believe that SHI Li-chen, on the whole, China’s pharmaceutical industry is still the pace of development in accordance with the established development, but we can analyze the fundamentals of composition, according to the relevant data: 1 the competitive advantage of API in the world market level is rapidly reduced (2) most of our production capacity and products of chemical drugs are generic basic 3 Although the gradual increase in the proportion of Chinese medicine, but a relatively small base 4 Most of the data is GuoZiHao business, deteriorating living environment for SMEs 5 The data base is in the low-end competition in the pharmaceutical products, high-end products basically monopolized imports The current competitive landscape of China’s pharmaceutical industry is low-level redundant construction, manufacturers everywhere, vicious competition, price wars dominate the market, low-cost generic drugs and medicine into the mainstream, market disorder, pharmaceutical companies within the industry to survive hard in vain. Normalized low-cost competition, will be a long-term future of China’s pharmaceutical industry in the normal period of time, because of China’s pharmaceutical busines